Press Room

For Media Inquiries:

Contact Julie Livingston julie@medshadow.org | 347-239-0249

Press Releases:

MedShadow Receives Spring 2017 Digital Health Merit Award for 2 Part Investigative Series

June 16, 2017, New York, NY – MedShadow Foundation has received a Spring 2017 Digital Health Awards Merit designation for its two part series, Hide And Don’t Seek: Why Are Many Side Effects Kept From the Public by Padma Nagappan. In the series, Nagappan addresses how many side effects Continue Reading →

Suzanne Robotti, President, MedShadow Foundation, Named to FDA Drug Safety and Risk Management Advisory Committee

February 14, 2017, New York, NY – The Food and Drug Administration (FDA) has named Suzanne Robotti, founder and president of MedShadow Foundation, to its Drug Safety and Risk Management Advisory Committee as the Consumer Representative. Next month, she will attend her first hearing where a prescription opioid drug will Continue Reading →

MedShadow Receives Spring 2016 Digital Health Award for Its Website

June 13, 2016, New York, NY – MedShadow has been recognized with a Spring 2016 Digital Health Awards Silver designation for its website in the Nonprofit category. Winners were announced on June 10th.  Formerly known as the Web Health Awards, the Digital Health Awards are held twice each year – Continue Reading →

Prince’s Fentanyl Overdose & Public Misconceptions About Opioids

“There’s a straight line between the overprescribing of opioids, the public’s misconceptions about these drugs and the rapidly rising number of accidental deaths from opioid addiction.”

More Press Releases →

Media Appearances:

MedPage Today: FDA Panels Like Long-Acting Buprenorphine

A joint FDA advisory committee has voted in favor of approval of two long-acting buprenorphine formulations, though they expressed concerns about higher doses of both products. Suzanne Robotti, founder of the MedShadow Foundation and a consumer representative who voted against approving the drug at any dosage, said many questions remained unanswered. Read Su Robotti’s comments and the article in its entirety here.

MedPage Today: FDA Panel Urges Approval of Semaglutide for T2D

The FDA Drug Safety and Risk Management Advisory Committee voted 16-0 Wednesday, with one abstention, in favor of recommending approval of semaglutide, a GLP-1 receptor agonist for once-weekly injection in type 2 diabetes along with lifestyle changes. Suzanne Robotti, MedShadow serves as the committee’s Consumer Representative.

Another concern raised during Continue Reading →

Reader’s Digest: 6 Common Medications That Could Be to Blame for Your Weight Gain

There are sneaky things that cause weight gain that aren’t food or exercise. One of them may be prescription medication. Many common prescription drugs can cause some patients to pack on the pounds, though it’s unclear whether the drug causes weight gain or the propensity to gain weight is Continue Reading →

Next Avenue: How Acupuncture Can Reduce the Need for Medicine

A common concern for patients who integrate different treatment types is the divided loyalty they feel between their practitioners. Even well-informed patients can be overwhelmed, and there is a common misconception that conventional medicine and “complementary” modalities such as acupuncture are mutually exclusive. Read here.